Patents Assigned to NOVAROCK BIOTHERAPEUTICS, LTD.
  • Anti-CLauDiN 18 antibodies and methods of use thereof
    Patent number: 11407828
    Abstract: Antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for use in antibody-based immunotherapies of a disease associated with aberrant expression of CLDN18.2 are disclosed.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: August 9, 2022
    Assignee: NovaRock Biotherapeutics, Ltd.
    Inventors: Han Li, Ming Lei, Yi Pei, Haichun Huang
  • Anti-interleukin-23 P19 antibodies and methods of use thereof
    Patent number: 11396541
    Abstract: The present disclosure provides antibodies and antibody fragments thereof that bind to IL-23p19. The disclosed antibodies and antibody fragments thereof can modulate a biological activity of the IL-23 receptor signaling axis and are therefore useful for the treatment of immune-mediated inflammatory disorders.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: July 26, 2022
    Assignee: NOVAROCK BIOTHERAPEUTICS, LTD.
    Inventors: Haichun Huang, Ming Lei, Yi Pei, Han Li